Education
About Us
Working with TipRanks
Follow Us
Quanterix Corporation (QTRX)
NASDAQ:QTRX
QTRX Stock Chart & Stats
$4.76
-$0.25(-2.12%)
At close: 4:00 PM EST
$4.76
-$0.25(-2.12%)
Day’s Range― - ―
52-Week Range$4.05 - $8.77
Previous CloseN/A
Volume125.22K
Average Volume (3M)509.80K
Market Cap
$223.43M
Enterprise Value$230.83M
Total Cash (Recent Filing)$118.23M
Total Debt (Recent Filing)$37.24M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
May 12, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding46,939,976
10 Day Avg. Volume461,526
30 Day Avg. Volume509,801
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.92
Price to Sales (P/S)1.95
P/FCF Ratio-3.40
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue1.66
Enterprise Value/Gross Profit3.57
Enterprise Value/Ebitda-2.34
Forecast
1Y Price Target
$7.50Price Target Upside57.56% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-1.27
Revenue Forecast (FY)$170.84M
Bulls Say, Bears Say
Bulls Say
Leadership And Commercialization FocusAppointment of Everett Cunningham as president and CEO, with a background commercializing consumer-facing diagnostics, signals a stronger commercial focus that may accelerate diagnostics and research tools commercialization.
Product OutperformanceCore Simoa instrument and assay sales drove the majority of the upside versus guidance, supporting revenue momentum in the research tools segment.
Regulatory Pathway For DiagnosticsFiling of the LucentAD Alzheimer's diagnostic with the FDA creates a potential regulatory pathway toward a commercial diagnostic offering, enhancing product diversification prospects.
Bears Say
Analyst Caution On Strategy And ExecutionAnalyst maintains a hold rating and is cautious until the new CEO establishes clear priorities and demonstrates consistent execution, reflecting investor concern about strategic clarity and performance reliability.
Funding Headwinds In Academic And Government MarketsGuidance that assumes weak market conditions and points to expected softness in U.S. academic and government funding signals potential revenue pressure from reduced grant-supported purchasing.
Spatial Biology Underperformance And Acquisition RiskThe spatial biology product line has underperformed relative to other segments and investor opposition to the related acquisition raises concerns about the business's strategic fit and integration.
Quanterix News
QTRX FAQ
What was Quanterix Corporation’s price range in the past 12 months?
Quanterix Corporation lowest stock price was $4.05 and its highest was $8.77 in the past 12 months.
What is Quanterix Corporation’s market cap?
Quanterix Corporation’s market cap is $223.43M.
When is Quanterix Corporation’s upcoming earnings report date?
Quanterix Corporation’s upcoming earnings report date is May 12, 2026 which is in 60 days.
How were Quanterix Corporation’s earnings last quarter?
Quanterix Corporation released its earnings results on Mar 02, 2026. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.449 by -$0.041.
Is Quanterix Corporation overvalued?
According to Wall Street analysts Quanterix Corporation’s price is currently Undervalued.
Does Quanterix Corporation pay dividends?
Quanterix Corporation does not currently pay dividends.
What is Quanterix Corporation’s EPS estimate?
Quanterix Corporation’s EPS estimate is -0.47.
How many shares outstanding does Quanterix Corporation have?
Quanterix Corporation has 46,939,976 shares outstanding.
What happened to Quanterix Corporation’s price movement after its last earnings report?
Quanterix Corporation reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.449. Following the earnings report the stock price went down -7.267%.
Which hedge fund is a major shareholder of Quanterix Corporation?
Currently, no hedge funds are holding shares in QTRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Quanterix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$7.50 (57.56% Upside)
$7.50 (57.56% Upside)
Hedge Fund Trend
Increased
By 531.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.83%
12-Months-Change
Fundamentals
Return on Equity
-29.28%
Trailing 12-Months
Asset Growth
-9.69%
Trailing 12-Months
Company Description
Quanterix Corporation
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
QTRX Company Deck
QTRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: GAAP revenue growth (+25% YoY), meaningful diagnostic milestones (CMS reimbursement and FDA 510(k) submission), product launches, margin improvement, synergy realization and a strong cash position are positive signs. However, significant organic revenue declines (-22% overall; Simoa -22%; Spatial -23%/ -16% ex-agreement), soft pharma demand (-21%), a dilutive terminated agreement and continued adjusted EBITDA losses highlight material near-term challenges. Management emphasized synergy delivery, improved cash usage and an expectation of cash-flow breakeven in H2 2026, but pro forma top-line growth guidance is modest (~+2% at midpoint) and execution against diagnostic commercialization and market recovery remains critical.View all QTRX earnings summariesQTRX Stock 12 Month Forecast
Average Price Target
$7.50
▲(57.56% Upside)
Technical Analysis
Viemed Healthcare
―
Nano-X Imaging
―
Outset Medical
―
908 Devices
―
TriSalus Life Sciences
―
Ownership Overview
7.12% Insiders
16.83% Mutual Funds
33.46% Other Institutional Investors
32.01% Public Companies and
Individual Investors